Merck to increase workforce at Indian sites by year end

Published On 2025-03-01 10:24 GMT   |   Update On 2025-03-01 10:25 GMT

Drug Maker Merck expects to boost employment in India with increment in its workforce across its India sites by the end of the year, a senior executive of the company said.

At the BioAsia conference in India's Telangana state, Dave Williams, Executive Vice President said, "By the end of this year, we expect to have roughly 2,700 employees. And in a couple of years, I fully expect we'll double that number or more."

Merck's India sites, which together employ around 1,800 people, focus on multiple therapy areas including oncology, diabetes, vaccines and animal health, as well as technology-related centers.
The U.S. drugmaker opened a new technology center in the southern Indian city of Hyderabad this week, Reuters reported.
Read also: Merck gets positive EU CHMP opinion for Pneumococcal vaccination in adults
Williams, who heads the information and digital department, said the company is looking to hire "digital innovators" who can help business partners understand the role technology can play in reducing the time taken to get new treatments to patients.

Read also: Merck gets USFDA Priority Review for application for Keytruda plus standard of care as Perioperative treatment for Resectable Locally Advanced Head, Neck Squamous Cell Carcinoma



Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News